| Business Type | Exporter, Supplier, Retailer |
| Usage | Treatment Of Unresectable Or Metastatic Melanoma With BRAF V600E Mutation,Metastatic Non-small Cell Lung Cancer With BRAF V600E Mutation,Anaplastic Thyroid Cancer With BRAF V600E Mutation |
| Country of Origin | India |
| Packaging Size | 120 Capsules In Box |
| Click to view more | |
Product Details
COMPOSITION:
\\n\\n
Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg
\\n\\n
INDICATION:
\\n\\n
LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
\\n\\n
LuciDabra is indicated, in combination with trametinib, for:
\\n\\n
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n\\n
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.
\\n\\n
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
\\n\\n
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
\\n\\n
Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.COMPOSITION:
\\n\\n
Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg
\\n\\n
INDICATION:
\\n\\n
LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
\\n\\n
LuciDabra is indicated, in combination with trametinib, for:
\\n\\n
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n\\n
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.
\\n\\n
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
\\n\\n
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
\\n\\n
Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.COMPOSITION:
\\n\\n
Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg
\\n
INDICATION:
\\n
LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
\\n\\n
LuciDabra is indicated, in combination with trametinib, for:
\\n\\n
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n\\n
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.
\\n\\n
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
\\n\\n
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
\\n\\n
Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.
